Abstract A070: A phase 1/2a, open-label, dose-escalation study of EC-18 in patients with metastatic breast cancer for the prevention of chemotherapy-induced neutropenia

2019 ◽  
Author(s):  
Sung-Bae Kim ◽  
Myung-Hwan Kim
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Dose Escalation ◽  
Phase 1 ◽  
Metastatic Breast ◽  
Open Label ◽  
Dose Escalation Study ◽  
Label Dose ◽  
Chemotherapy Induced Neutropenia

Phase 1 Dose-Escalation Study of Triweekly Nab-Paclitaxel Combined With S-1 for HER2-Negative Metastatic Breast Cancer

2020 ◽  
Vol 20 (6) ◽  
pp. 448-453
Author(s):  
Masami Morimoto ◽  
Hiroaki Toba ◽  
Mariko Aoyama ◽  
Misako Nakagawa ◽  
Hirokazu Takechi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Dose Escalation ◽  
Phase 1 ◽  
Metastatic Breast ◽  
Dose Escalation Study

scholarly journals A phase 1/2, open‐label, dose‐escalation study of midostaurin in children with relapsed or refractory acute leukaemia

2018 ◽  
Vol 185 (3) ◽  
pp. 623-627 ◽  
Author(s):  
C. Michel Zwaan ◽  
Stefan Söderhäll ◽  
Benoit Brethon ◽  
Matteo Luciani ◽  
Carmelo Rizzari ◽  
...  
Keyword(s):  
Dose Escalation ◽  
Acute Leukaemia ◽  
Phase 1 ◽  
Open Label ◽  
Dose Escalation Study ◽  
Label Dose

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors

2018 ◽  
Vol 81 (4) ◽  
pp. 727-737 ◽  
Author(s):  
Frederik Marmé ◽  
Carlos Gomez-Roca ◽  
Kristina Graudenz ◽  
Funan Huang ◽  
John Lettieri ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Dose Escalation ◽  
Phase 1 ◽  
Open Label ◽  
Dose Escalation Study ◽  
Label Dose
Sign in / Sign up

Export Citation Format

Share Document